Hints and tips:
Related Special Reports
...To be evaluated, companies must submit their products’ complete R&D documentation and code....
...Patients with terminal breast cancer in England will miss out on a new drug already approved in Scotland, after spending watchdog NICE said Enhertu, developed by Japanese pharma company Daiichi Sankyo and...
...The ruling came after Escobar Inc, the company set up by his brother, filed an application in 2021 with the European Union Intellectual Property Office (EUIPO) for registration of the word sign Pablo Escobar...
...“NHS England expected drug companies AstraZeneca and Daiichi Sankyo to offer this treatment at a price that would enable Nice to recommend its use,” NHS England said....
...Escobar Inc, a company set up by his brother Roberto, had filed an application in 2021 with the European Union Intellectual Property Office (EUIPO) to register “Pablo Escobar” as a trademark for goods and...
...Illumina said the company agreed “with the advocate general that the European Commission’s assertion of jurisdiction over this merger was improper”. Illumina bought Grail in 2021....
...Davis points to a long list of “more nimble” telehealth companies that also provide access to GLP-1 drugs, such as Noom, a direct-to-consumer weight-loss company with comparable subscription pricing to WW...
...That's pretty rare in business for a company to grow that much and change that little....
...The researchers developed a molecule known as a peptide — a building block of proteins — to weaken CRAB’s outer membrane....
...Another 50 cents is collected by the merchant acquirer, or companies such as Block or Stripe that provide the shop’s point-of-sale service system....
...Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded....
...Contributions from the company’s acquisitions — notably the $43bn purchase of cancer biotechnology company Seagen — have yet to move the needle....
...ETFs are having tremendous success in the industry as low-cost, tax-efficient portfolio building blocks,” he added....
...J&J’s medtech division has outstripped the growth of the company’s drugs and diagnostics business, generating $30.4bn in sales last year, or 35 per cent of group revenues....
...The technology also has considerable long-term potential to make novel substances at scale for drugs such as antibiotics, scientists said....
...The hard-pressed US group was forced to take Boots off the block last year, with pensions complexity cited alongside choppy markets. One of these problems, at least, has been fixed....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Investor worries about the impact of weight loss drugs on snack companies are overdone. Cigarette makers and oil and gas drillers are surviving bigger existential threats remarkably well....
Decision finds lawmakers over-reached with statewide prohibition on downloads
...Buidl’s yield and BlackRock’s backing make it far higher quality collateral than a stablecoin issued by an unregulated far-off company....
...China has powers to block the export of ByteDance’s algorithms that power TikTok and Beijing’s commerce ministry said last year it would “firmly oppose” a forced sale by ByteDance....
...One is that Apple blocks the distribution of some apps and services that might threaten its model....
...The EU will sabotage Hungary’s economy if Budapest blocks fresh aid to Ukraine at a summit this week....
...Soundbite of the week: Physician, heal thyself While Ripple Labs was launching its stablecoin, the company was still battling the SEC over its hostile stance towards crypto....
...Roche plans to buy immunology company Telavant from Roivant Sciences and Pfizer for more than $7bn, as the drugmaker’s new chief executive seeks to replenish its drug pipeline....
International Edition